Correction in bold and underline.

Abstract
The mean change of HAMD-17 score was significantly different between two groups favoring PGATx by \(-4.0\) point of difference \((p = 0.036)\) at the end of treatment. The mean change in the FIBSER score from baseline was significantly different between two treatment groups favoring PGATx by \(-2.5\) point of difference \((p = 0.001)\). The response rate \((64.7\% \text{ vs. } 39.6\%, p = 0.014)\) were also significantly higher in PGATx than in TAU at the end of treatment, while the remission rate was numerically higher in PGATx than in TAU groups without statistical difference \((39.2\% \text{ vs. } 25.0\%, p = 0.147)\). The reason for early drop-out associated with adverse events was also numerically higher in TAU \((n = 9, 50.0\%)\) than in PGATx \((n = 4, 30.8\%)\).

P. 473: Right column, line 21
From "The intention-to-treat (ITT) population consisted of all patients who had at least one post-treatment assessment for effectiveness during the study. The effectiveness evaluation was based on the analyses with ITT on last observation carried forward."
To "The effectiveness was analyzed based on intention-to-treat (ITT) population with last observation carried forward."

: Line 25
Added: "The significance level was set at < 0.05 and statistical software program was IBM SPSS Statistics v20."

P. 473: Right column, Last paragraph
From "There were no significant treatment group differences for any baseline demographic findings including employment, religion, and economic status and so on. Likewise, there were no significant treatment group differences for any clinical characteristics such as depressive symptomatology, family history of psychiatric diagnosis, somatic symptoms, and functional impairment, and so on."
To "There were no substantial differences in demographic and clinical characteristics between PGATx and TAU groups (Table 1)."

P. 474: Primary endpoint

| From         | To       |
|--------------|----------|
| \(-4.1\) point | \(-4.0\) point |
| \(p = 0.010\) | \(p = 0.036\) |
| \(p = 0.028\) | \(p = 0.001\) |

P. 474: Secondary endpoint

| From | To |
|------|----|
| 28.1\% | 25.1\% |
| 19.9\% | 14.2\% |
 Left column line 2
\[ p = 0.071 \]

| From | To |
|------|----|
| \[ p = 0.147 \] | |

Left column line 3
The mean changes from baseline to the endpoint in PHQ-9 total scores in the PGATx and TAU were significantly different between the two groups favoring PGATx by \(-3.8\) point of difference \((p = 0.011)\) (Table 2).

| From | To |
|------|----|
| The mean changes from baseline to the endpoint in PHQ-9 total scores in the PGATx and TAU were marginally different between the two groups favoring PGATx by \(-3.8\) point of difference \((p = 0.054)\) (Table 2). |

Left column line 7
The mean changes from baseline to the endpoint in total CGI-S score in the PGATx and TAU were significantly different between the two groups favoring PGATx by \(-1.0\) point of difference \((p = 0.002)\) (Table 2).

| From | To |
|------|----|
| The mean changes from baseline to the endpoint in total CGI-S score in the PGATx and TAU were significantly different between the two groups favoring PGATx by \(-1.0\) point of difference \((p = 0.021)\) (Table 2). |

Left column line 11
The mean changes from baseline to the endpoint in GAD-7 total scores in the PGATx and TAU were significantly different between the two groups favoring PGATx by \(-2.1\) point of difference \((p = 0.033)\) (Table 2).

| From | To |
|------|----|
| The mean changes from baseline to the endpoint in GAD-7 total scores in the PGATx and TAU were significantly different between the two groups favoring PGATx by \(-2.1\) point of difference \((p = 0.047)\) (Table 2). |

Right column Line 2
The mean changes from baseline to the endpoint in SDS total scores in the PGATx and TAU were significantly but marginally different between the two groups favoring PGATx by \(-6.3\) point of difference \((p = 0.048)\) (Table 2).

| From | To |
|------|----|
| The mean changes from baseline to the endpoint in SDS total scores in the PGATx and TAU were not significantly different between the two groups favoring PGATx by \(-3.6\) point of difference \((p = 0.088)\) (Table 2). |

Right column Line 6
The proportion of patients showing 1 or 2 in the CGI-I score at the end of treatment was also significantly different between the two groups favoring PGATx by \(-2.1\) point of difference \((p = 0.039)\) (Table 2).

| From | To |
|------|----|
| The proportion of patients showing 1 or 2 in the CGI-I score at the end of treatment was not significantly different between the two groups favoring PGATx by \(-12.9\)% point of difference \((p = 0.197)\) (Table 2). |

Right column Line 10
However, the mean changes from baseline to the endpoint in PHQ-15 total scores in the PGATx and TAU were not significantly different between the two groups but numerically favoring PGATx by \(-1.7\) point of difference \((p = 0.153)\) (Table 2).

| From | To |
|------|----|
| The mean changes from baseline to the endpoint in PHQ-15 total scores in the PGATx and TAU were not significantly different between the two groups but numerically favoring PGATx by \(-1.7\) point of difference \((p = 0.239)\) (Table 2). |

Right column Line 15
The proportion of patients showing 2 or less in the FIBSER frequency \((p = 0.0346)\), intensity \((p = 0.0001)\), and burden \((p = 0.0001)\) sub-scores at…………….

| From | To |
|------|----|
| The proportion of patients showing 2 or less in the FIBSER frequency \((p < 0.001)\), intensity \((p < 0.001)\), and burden \((p < 0.001)\) sub-scores at…………….

Right column line 19
18.1%, 69%, and 69.7% 12.9%, 42.1%, and 42.3%

P. 476: Discussion

"Furthermore, PGATx was associated with significantly more improvement in most secondary endpoint (the changes of PHQ-9, SDS, CGI-S, and GAD scores from baseline to the end of treatment as well as the proportion of patients showing 1 or 2 in the CGI-I score) excluding the change of PHQ-15 score from baseline to the end of treatment."  

Furthermore, PGATx was also associated with significantly or numerically more improvement in secondary endpoints.

P. 477: Discussion

combinatorial pharmacogenomic
In Table 1: correction in bold and underline. Omitted FIBSER was added.

Table 1. Baseline characteristics of the subjects in the study

| Characteristic                           | PGATx (n = 52)       | TAU (n = 48)       | p value |
|------------------------------------------|----------------------|-------------------|---------|
| Age (yr)                                 | 44.2 ± 16.1          | 43.9 ± 13.8       | 0.900   |
| Sex, female                              | 40 (76.9)            | 35 (72.9)         | 0.653   |
| Onset age (yr)                           | 36.9 ± 15.5          | 38.6 ± 14.2       | 0.604   |
| Age at first diagnosis of MDD (yr)       | 36.8 ± 13.9          | 39.3 ± 14.1       | 0.430   |
| Number of admission                      | 1.3 ± 0.5            | 1.4 ± 0.5         | 0.827   |
| History of admission                     | 6 (11.5)             | 5 (10.4)          | 1.000   |
| Number of previous antidepressant trial for current episode | 2.5 ± 2.2 | 2.1 ± 1.5 | 0.633 |
| Family history of psychiatric disorders  | 0.687                |                   |         |
| Yes                                      | 10 (19.2)            | 8 (16.7)          |         |
| Not answered                             | 27 (51.9)            | 29 (60.4)         |         |
| Job                                      | 15 (28.8)            | 11 (22.9)         |         |
| Yes                                      | 11 (21.2)            | 14 (29.2)         | 0.382   |
| No                                       | 37 (71.2)            | 33 (68.8)         |         |
| Not answered                             | 4 (7.7)              | 1 (2.1)           |         |
| Status of marriage                       | 0.362                |                   |         |
| Married                                  | 23 (44.2)            | 26 (54.2)         |         |
| Single                                   | 12 (23.1)            | 12 (25.0)         |         |
| Separation                               | 0 (0.0)              | 1 (2.1)           |         |
| Spouse death                             | 1 (1.9)              | 1 (2.1)           |         |
| Leave                                    | 4 (7.7)              | 4 (8.3)           |         |
| Not answered                             | 12 (23.1)            | 4 (8.3)           |         |
| Religion                                 | 0.291                |                   |         |
| Christian                                | 3 (5.8)              | 6 (12.5)          |         |
| Buddhism                                 | 3 (5.8)              | 6 (12.5)          |         |
| Catholic                                 | 8 (15.4)             | 4 (8.3)           |         |
| None                                     | 29 (55.8)            | 28 (58.3)         |         |
| Not answered                             | 9 (17.3)             | 4 (8.3)           |         |
| Economic status                          | 0.238                |                   |         |
| Covered by livelihood protection         | 11 (21.2)            | 12 (25.0)         |         |
| Middle                                   | 31 (59.6)            | 33 (68.8)         |         |
| Superior                                 | 2 (3.8)              | 0 (0.0)           |         |
| Not answered                             | 8 (15.4)             | 3 (6.2)           |         |
| Type of MDD                              | 0.394                |                   |         |
| Melancholic                              | 39 (75.0)            | 39 (81.2)         |         |
| Atypical                                 | 13 (25.0)            | 8 (16.7)          |         |
| Others                                   | 0 (0.0)              | 1 (2.1)           |         |
| Antidepressants                          | 0.062                |                   |         |
| SSRI                                     | 16 (30.8)            | 21 (43.8)         |         |
| SNRI                                     | 24 (46.2)            | 18 (37.5)         |         |
| DNRI                                     | 7 (13.5)             | 1 (2.1)           |         |
| NaSSa                                    | 0 (0.0)              | 3 (6.3)           |         |
| Others                                   | 5 (9.2)              | 5 (10.4)          |         |
| HAMD                                     | 24.5 ± 4.6           | 23.1 ± 5.0        | 0.159   |
| CGI-s                                    | 4.9 ± 0.8            | 4.6 ± 0.7         | 0.047   |
| PHQ-9                                    | 20.9 ± 3.8           | 19.1 ± 5.3        | 0.096   |
| PHQ-15                                   | 11.4 ± 4.9           | 10.5 ± 5.8        | 0.279   |
| GAD-7                                    | 8.7 ± 5.0            | 7.6 ± 4.6         | 0.274   |
| SDS                                      | 17.3 ± 8.5           | 15.9 ± 7.7        | 0.314   |
| FIBSER                                   | 6.5 ± 4.3            | 6.6 ± 4.1         | 0.881   |

Values are presented as mean ± standard deviation or number (%).

PGATx, pharmacogenetic-based antidepressant treatment; TAU, treatment as usual; MDD, major depressive disorder; SSRI, serotonin selective reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; DNRI, dopamine and norepinephrine reuptake inhibitor; NaSSa, noradrenergic specific serotonin antagonist; HAMD, Hamilton Depression Rating scale; CGI-S, Clinical Global Impression-Severity; PHQ-9/15, Patient Health Questionnaire-9/15; GAD-7, General Anxiety Disorder-7; SDS, Sheehan Disability Scale; FIBSER, Frequency, Intensity, Burden of Side Effects Rating.
In Table 2: correction in bold and underline

**Table 2. Summary of the primary and secondary endpoints in the study**

| Endpoints | PGATx (n = 52) | TAU (n = 48) | F value | p value |
|-----------|----------------|--------------|---------|---------|
| HAMD†     | −16.1 ± 6.8    | −12.1 ± 8.2  | 4.516   | 0.036   |
| FIBSER†   | −4.1 ± 5.3     | −1.6 ± 5.9   | 11.097  | 0.001   |
| PHQ-9†    | −13.6 ± 6.8    | −9.8 ± 7.8   | 3.792   | 0.054   |
| PHQ-15†   | −8.1 ± 5.0     | −6.4 ± 6.8   | 1.403   | 0.239   |
| CGI-S†    | −3.3 ± 1.4     | −2.3 ± 1.8   | 5.510   | 0.021   |
| GAD-7†    | −6.2 ± 4.9     | −4.1 ± 4.7   | 4.050   | 0.047   |
| SDS†      | −9.9 ± 7.8     | −6.3 ± 9.0   | 2.978   | 0.088   |
| The proportion of patients showing 1 or 2 in the CGI-I score*‡ | 37 (71.2) | 28 (58.3) | - | 0.197 |

Values are presented as mean ± standard deviation or number (%).
PGATx, pharmacogenetic-based antidepressant treatment; TAU, treatment as usual; PHQ-9/15, Patient Health Questionnaire-9/15; CGI-S, Clinical Global Impression-Severity; GAD-7, General Anxiety Disorder-7; SDS, Sheehan Disability Scale; FIBSER, Frequency, Intensity, Burden of Side Effects Rating; HAMD, Hamilton Depression Rating scale. *Cochran-Mantel-Haenszel test; †The change from baseline to the end of treatment. Proportion at the end of treatment.

**Fig. 2.** Correction of proportion: In order from the left

| 71.7, 43.6, 45.5, 25.6 | 64.7, 39.6, 39.2, 25.0 |

**Fig. 3.** Correction of proportion: In order from the left

| 94.8, 76.7, 92.3, 23.3, 89.7, 20 | 96.2, 83.3, 94.2, 52.1, 92.3, 50.0 |